Orexins/Hypocretins: Pain regulation and cellular actions

Lih Chu Chiou*, Hsin Jung Lee, Yu Cheng Ho, Shih Pin Chen, Yan Yu Liao, Chia Hau Ma, Pi Chuan Fan, Jong Ling Fuh, Shuu Jiun Wang

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

81 Scopus citations


Orexin A and B (also named hypocretin 1 and 2) are 33 and 28 amino acid-containing neuropeptides, respectively, derived from prepro-orexin (prepro-hypocretin) which is localized in the lateral and perifonical areas of the hypothalamus. Two G-protein coupled receptor subtypes, OX1 and OX2, were identified. Orexin-containing fibers and OX receptors are widely distributed in the central nervous system. Orexins have been implicated in the arousal, rewarding, energy homeostasis, autonomic central control and antinociceptive systems. Subtype-selective peptide agonists and antagonists and non-peptide antagonists, but not non-peptide agonists, have been developed. This review summarizes the studies investigating the antinociceptive effects of orexins in various animal models of pain, including trigeminovascular pain, and their cellular mechanisms. Orexins are antinociceptive at both spinal and supraspinal levels. The antinociceptive effect of orexin A is comparable to opioids but orexin B is less or not effective. This effect is opioid-independent and mainly mediated through OX1 receptors. Some animal studies suggest that endogenous orexins may be released during postoperative and inflammatory, but not acute, pain states, or during some stress conditions, which may contribute to stress-induced analgesia. Purinergic P2X and glycine receptors are proposed to be involved in orexin-induced spinal antinociception. The supraspinal sites of actions might involve the posterior hypothalamus, which contributes to the trigeminovascular nociception, and the ventrolateral periaqueductal gray, which mediates descending pain inhibition. Endocannobinoids and nociceptin/orphanin FQ were found to interplay with orexins in nocicpetive processing. Further studies are required to elucidate the receptor subtype-specific mechanism(s) and clinical implications of orexin-induced antinociception.

Original languageEnglish
Pages (from-to)3089-3100
Number of pages12
JournalCurrent Pharmaceutical Design
Issue number28
StatePublished - 2010


  • Cluster headache
  • Endocannabinoids
  • Migraine
  • Nociceptin/Orphanin FQ
  • OX1/OX2 receptors
  • Orexins/Hypocretins
  • Pain


Dive into the research topics of 'Orexins/Hypocretins: Pain regulation and cellular actions'. Together they form a unique fingerprint.

Cite this